“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early breast cancer.

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo ...

Daiichi Sankyo Company, Limited ( OTCPK:DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions October 21, 2025 8:00 AM EDT ...

The Nifty 50 may have entered a consolidation phase in the short term, possibly before resuming its uptrend. A decisive fall ...

A pharmacist, a registered scientist and his own former office manager are among the people accused of running a fraudulent Covid-19 testing ...

A New Era in the Treatment of Muscle Invasive Bladder Cancer. Discussant of LBA2 - Perioperative (Periop) Enfortumab Vedotin ...

Malik, 57, is accused of establishing the 'cash cow' firm alongside a pharmacist, a registered scientist and his own former ...

Trains have been delayed on every Metra commuter line in the Chicago area during the Tuesday evening rush, due to a positive train control system outage. Metra officials said, beginning around 5 p.m., ...